Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: a Japanese survey (Q43582944)

24 November 2017

title

Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: a Japanese survey (English)

1 reference

24 November 2017

1 reference

Y Kanda

1

1 reference

24 November 2017

Y Omuro

2

1 reference

24 November 2017

E Baba

3

1 reference

24 November 2017

K Oshima

4

1 reference

24 November 2017

K Nagafuji

5

1 reference

24 November 2017

Y Heike

6

1 reference

24 November 2017

Y Takaue

7

1 reference

24 November 2017

T Sasaki

8

1 reference

24 November 2017

H Sakamaki

9

1 reference

24 November 2017

M Harada

10

1 reference

24 November 2017

language of work or name

English

0 references

publication date

7 April 2008

1 reference

Bone Marrow Transplantation

24 November 2017

published in

1 reference

24 November 2017

volume

42

1 reference

24 November 2017

issue

2

1 reference

24 November 2017

page(s)

99-103

1 reference

Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.94

The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.94

Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.94

Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.94

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.94

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.94

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.94

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.94

Immunotherapy for pancreatic cancer: current concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.94

Regression of an unresectable pancreatic tumor following nonmyeloablative allogeneic peripheral-blood stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.94

Nonmyeloablative allogeneic stem cell transplantation for patients with unresectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.94

Graft-versus-tumor effect against advanced pancreatic cancer after allogeneic reduced-intensity stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.94

HLA-identical stem cell transplantation: is there an optimal CD34 cell dose?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.94

Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.94

Prognostic indicators for survival after resection of pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.94

The second international meeting on allogeneic transplantation in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.94

7 January 2021

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.94

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.94

7 January 2021

Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.94

7 January 2021

In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.94

7 January 2021

Identifiers

DOI

10.1038/BMT.2008.94

1 reference

Dimensions Publication ID

24 November 2017

1006445509

0 references

1 reference